Compare Ascendis Pharma A/S (ASND) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.5. Which is the better fit depends on your goals.
| ASND | VWO | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $61.24 |
52-Week Low | $163.32 | $49.54 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
VWO trades at $59.89, up 0.67% today, with a bullish technical signal from moving averages. The ETF offers broad emerging markets exposure with a low 0.06% expense ratio and a 2.4% dividend yield. Recent news highlights strong capital inflows into emerging markets and comparisons with peers like EEM, emphasizing VWO's cost advantage and exclusion of South Korean stocks due to index methodology.
The outlook for VWO is supported by diversification benefits and attractive valuations in emerging markets, but risks include geopolitical tensions and index composition gaps. Analyst sentiment is mixed, with performance heavily influenced by regional allocations and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
